|
|
| [PMID]: | 27911450 |
| [Au] Autor: | Kaliki S; Shields CL |
| [Ad] Endereço: | The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India. |
| [Ti] Título: | Uveal melanoma: relatively rare but deadly cancer. |
| [So] Source: | Eye (Lond);31(2):241-257, 2017 Feb. | | [Is] ISSN: | 1476-5454 |
| [Cp] País de publicação: | England |
| [La] Idioma: | eng |
| [Ab] Resumo: | Although it is a relatively rare disease, primarily found in the Caucasian population, uveal melanoma is the most common primary intraocular tumor in adults with a mean age-adjusted incidence of 5.1 cases per million per year. Tumors are located either in iris (4%), ciliary body (6%), or choroid (90%). The host susceptibility factors for uveal melanoma include fair skin, light eye color, inability to tan, ocular or oculodermal melanocytosis, cutaneous or iris or choroidal nevus, and BRCA1-associated protein 1 mutation. Currently, the most widely used first-line treatment options for this malignancy are resection, radiation therapy, and enucleation. There are two main types of radiation therapy: plaque brachytherapy (iodine-125, ruthenium-106, or palladium-103, or cobalt-60) and teletherapy (proton beam, helium ion, or stereotactic radiosurgery using cyber knife, gamma knife, or linear accelerator). The alternative to radiation is enucleation. Although these therapies achieve satisfactory local disease control, long-term survival rate for patients with uveal melanoma remains guarded, with risk for liver metastasis. There have been advances in early diagnosis over the past few years, and with the hope survival rates could improve as smaller tumors are treated. As in many other cancer indications, both early detection and early treatment could be critical for a positive long-term survival outcome in uveal melanoma. These observations call attention to an unmet medical need for the early treatment of small melanocytic lesions or small melanomas in the eye to achieve local disease control and vision preservation with the possibility to prevent metastases and improve overall patient survival. |
| [Mh] Termos MeSH primário: |
Melanoma
Neoplasias Uveais
|
| [Mh] Termos MeSH secundário: |
Distribuição por Idade
Terapia Combinada
Seres Humanos
Incidência
Iridectomia/métodos
Melanoma/epidemiologia
Melanoma/etiologia
Melanoma/patologia
Melanoma/terapia
Radiocirurgia/métodos
Radioterapia/métodos
Fatores de Risco
Distribuição por Sexo
Proteínas Supressoras de Tumor/genética
Ubiquitina Tiolesterase/genética
Raios Ultravioleta/efeitos adversos
Neoplasias Uveais/epidemiologia
Neoplasias Uveais/etiologia
Neoplasias Uveais/patologia
Neoplasias Uveais/terapia
|
| [Pt] Tipo de publicação: | JOURNAL ARTICLE; REVIEW |
[Nm] Nome de substância:
| 0 (Tumor Suppressor Proteins); EC 3.1.2.15 (BAP1 protein, human); EC 3.4.19.12 (Ubiquitin Thiolesterase) |
| [Em] Mês de entrada: | 1707 |
| [Cu] Atualização por classe: | 170718 |
[Lr] Data última revisão:
| 170718 |
| [Sb] Subgrupo de revista: | IM |
| [Da] Data de entrada para processamento: | 161203 |
| [St] Status: | MEDLINE |
| [do] DOI: | 10.1038/eye.2016.275 |
| |
|
|
